Microarrays

PEPperCHIP® Pan-Transglutaminase Microarray


(Standard microarray)

Order
Quantity
Price
Status
1 Chip 475 € available


Documents
Art. No. P111
Background info The Microarray covers 6 transglutaminase variants (hFXIII, hTG1, hTG2, hTG3, hTG4 and hTG6) translated into overlapping peptides.

The protein sequences were elongated by neutral GSGSGSG linkers to avoid truncated peptides. The elongated protein sequences were translated into 15 aa peptides printed in duplicate with a max. peptide-peptide overlap of 14 aa for full epitope coverage.

- peptide length/overlap: 15 aa / 14 aa
- number of peptides/spots: 4,354 / 8,708
- HA, c-Myc and polio control peptides

PEPperCHIP Transglutaminase Microarray
Equipment Each PEPperCHIP® Peptide Microarray is marked with a microarray ID on the backside of the glass slide. The glass slide is accurately placed in an incubation tray with the microarray surface up if the microarray ID appears in the top right corner in a mirror view manner.
PEPperCHIP® Transglutaminase Microarray contains a single peptide array and is compatible with a 3/1-well PEPperCHIP® Incubation Tray.
Each PEPperCHIP® Transglutaminase Microarray further contains Polio, c-Myc and HA control peptides (42, 42 and 48 spots each control).
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy